EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

BMP9 potentiates immunotherapy in triple-negative breast cancer by suppressing Tregs infiltration via the PRKDC-CCL2 axis

Yiqing You, Lan Wei, Meng Dai, Guozhi Zhao, Kun Fan, Tingting Dang, Haoli Sun, Liang Zhang, Qian Li, Mengxin Sun, Xiaolu Li, Xiran He und 4 weitere

Cancer Letters · 2026

DOI: 10.1016/j.canlet.2025.218175 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2026. Verfasst von Yiqing You und 15 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Medical Diagnostics of Ministry of Education, Department of Laboratory Medicine, Chongqing Medical University, Chongqing, 400016, C…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Chemokine CCL2, T-Lymphocytes, Regulatory, Growth Differentiation Factor 2. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Chongqing Municipal Education Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunotherapy represents a pivotal strategy for triple-negative breast cancer (TNBC), yet its efficacy is constrained by the immunosuppressive tumor microenvironment (TME). In this study, we demonstrate that bone morphogenetic protein-9 (BMP9) inhibits tumor growth and reprograms the immune TME in orthotopic TNBC models, primarily by attenuating regulatory T cells (Tregs) infiltration. Tregs depletion abrogates si-BMP9-mediated tumor promotion. Mechanistically, BMP9 suppresses CCL2 expression in an exocrine-independent manner to restrict Tregs recruitment. We identify DNA-dependent protein kinase catalytic subunit (PRKDC) as a BMP9-binding transcriptional regulator. The interaction between PRKDC and BMP9 directly impedes CCL2 transcriptional activation by suppressing PRKDC phosphorylation and indirectly suppresses CCL2 expression via NF-κB pathway remodeling. Critically, BMP9 modulation and CCL2 targeting potentiates immunotherapy efficacy without observable toxicity. Our study unveils the BMP9-PRKDC-CCL2 axis as a master regulatory node for TNBC-Tregs crosstalk, providing a strategy to overcome immunotherapy resistance in TNBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsChemokine CCL2T-Lymphocytes, RegulatoryGrowth Differentiation Factor 2ImmunotherapyHumansFemaleAnimalsMiceTumor MicroenvironmentCell Line, TumorSignal TransductionGene Expression Regulation, NeoplasticXenograft Model Antitumor Assays

Stichwörter der Autor:innen

BMP9CCL2ImmunotherapyTNBCTregs

Substanzen

Chemokine CCL2Growth Differentiation Factor 2CCL2 protein, humanGDF2 protein, human

Autor:innen und Institutionen

  • Key Laboratory of Medical Diagnostics of Ministry of Education, Department of Laboratory Medicine, Chongqing Medical University, Chongqing, 400016, China.
  • Key Laboratory of Medical Diagnostics of Ministry of Education, Department of Laboratory Medicine, Chongqing Medical University, Chongqing, 400016, China; Chongqing Blood Center, Chongqing, 400052, China.
  • Department of Oncology, Chongqing Traditional Chinese Medicine Hospital, Chongqing, 400021, China; Chongqing Municipal Health Commission Key Laboratory for Translational Research in Integrated Chinese and Western Medici…
  • Department of Urology Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
  • Department of General surgery, Chongqing Hospital of Jiangsu Province Hospital, The People's Hospital of Qijiang District, Chongqing, China.
  • Chongqing Key Laboratory of Development and Utilization of Genuine Medicinal Materials in Three Gorges Reservoir Area, Chongqing Three Gorges Medical College, Chongqing, 404120, China. Electronic address: 20160010@cqtgm…

Förderung

  • National Natural Science Foundation of China
  • Chongqing Municipal Education Commission

Zitieren

APA

You, Y., Wei, L., Dai, M., Zhao, G., Fan, K., Dang, T., Sun, H., Zhang, L., Li, Q., Sun, M., Li, X., He, X., Yang, S., Zeng, T., Tang, J., & Zhang, Y. (2026). BMP9 potentiates immunotherapy in triple-negative breast cancer by suppressing Tregs infiltration via the PRKDC-CCL2 axis. Cancer Letters. https://doi.org/10.1016/j.canlet.2025.218175

Vancouver

You Y, Wei L, Dai M, Zhao G, Fan K, Dang T, et al. BMP9 potentiates immunotherapy in triple-negative breast cancer by suppressing Tregs infiltration via the PRKDC-CCL2 axis. Cancer Letters. 2026. doi:10.1016/j.canlet.2025.218175

BibTeX
@article{You2026,
  author = {You, Yiqing and Wei, Lan and Dai, Meng and Zhao, Guozhi and Fan, Kun and Dang, Tingting and Sun, Haoli and Zhang, Liang and Li, Qian and Sun, Mengxin and Li, Xiaolu and He, Xiran and Yang, Shiyu and Zeng, Tao and Tang, Jiafeng and Zhang, Yan},
  title = {BMP9 potentiates immunotherapy in triple-negative breast cancer by suppressing Tregs infiltration via the PRKDC-CCL2 axis},
  journal = {Cancer Letters},
  year = {2026},
  doi = {10.1016/j.canlet.2025.218175}
}
Kostenlos starten →